{Reference Type}: Case Reports
{Title}: Treating seronegative neuromyelitis optica spectrum disorder with inebilizumab: a case report.
{Author}: Lehrieder D;Zapantis N;Pham M;Schuhmann MK;Haarmann A;
{Journal}: Front Neurol
{Volume}: 14
{Issue}: 0
{Year}: 2023
{Factor}: 4.086
{DOI}: 10.3389/fneur.2023.1297341
{Abstract}: <B>UNASSIGNED: </B>Neuromyelitis optica spectrum disorder (NMOSD) is a devastating inflammatory disease of the central nervous system that is often severely disabling from the outset. The lack of pathognomonic aquaporin 4 (AQP4) antibodies in seronegative NMOSD not only hinders early diagnosis, but also limits therapeutic options, in contrast to AQP4 antibody-positive NMOSD, where the therapeutic landscape has recently evolved massively.<BR><B>UNASSIGNED: </B>We report a 56-year-old woman with bilateral optic neuritis and longitudinally extensive myelitis as the index events of a seronegative NMOSD, who was successfully treated with inebilizumab.<BR><B>UNASSIGNED: </B>Treatment with inebilizumab may be considered in aggressive seronegative NMOSD. Whether broader CD19-directed B cell depletion is more effective than treatment with rituximab remains elusive.